A case of choroidal metastasis from renal cell carcinoma significantly reduced by radiotherapy

Q4 Medicine IJU Case Reports Pub Date : 2024-12-06 DOI:10.1002/iju5.12819

Koichiro Kanazawa, Shinnosuke Oishi, Akihiko Sakamoto, Kuniaki Tanabe, Kazutaka Sugiyama, Akihiko Matsumoto, Akari Arakawa, Hiromi Matsunaga, Takafumi Harada, Haruki Kume

{"title":"A case of choroidal metastasis from renal cell carcinoma significantly reduced by radiotherapy","authors":"Koichiro Kanazawa, Shinnosuke Oishi, Akihiko Sakamoto, Kuniaki Tanabe, Kazutaka Sugiyama, Akihiko Matsumoto, Akari Arakawa, Hiromi Matsunaga, Takafumi Harada, Haruki Kume","doi":"10.1002/iju5.12819","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Choroidal metastasis from renal cell carcinoma is relatively rare and unresponsive to systemic treatment.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A man in his eighties with left renal cell carcinoma and pulmonary metastasis developed visual impairment in the left eye during primary treatment with ipilimumab and nivolumab followed by secondary treatment with cabozantinib. Consultation with an ophthalmologist revealed choroidal metastasis, which was subsequently treated with local radiotherapy (3 Gy × 10 Fr), resulting in a significant reduction in the metastatic lesions.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>If visual impairment arises while treating renal cell carcinoma, it is essential to consider the possibility of intraocular metastasis. In terms of treatment, local therapies such as radiotherapy should be taken into consideration.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"77-80"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Choroidal metastasis from renal cell carcinoma is relatively rare and unresponsive to systemic treatment.

Case presentation

A man in his eighties with left renal cell carcinoma and pulmonary metastasis developed visual impairment in the left eye during primary treatment with ipilimumab and nivolumab followed by secondary treatment with cabozantinib. Consultation with an ophthalmologist revealed choroidal metastasis, which was subsequently treated with local radiotherapy (3 Gy × 10 Fr), resulting in a significant reduction in the metastatic lesions.

Conclusion

If visual impairment arises while treating renal cell carcinoma, it is essential to consider the possibility of intraocular metastasis. In terms of treatment, local therapies such as radiotherapy should be taken into consideration.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

放疗后肾细胞癌脉络膜转移明显减少1例。

导言：肾细胞癌的脉络膜转移相对罕见且对全身治疗无反应。病例介绍：一名80多岁患有左肾细胞癌和肺转移的男子，在伊匹单抗和纳伏单抗的初级治疗中，左眼出现视力障碍，随后用卡博津替尼进行二次治疗。咨询眼科医生发现脉膜转移，随后进行局部放疗（3 Gy × 10 Fr），导致转移灶显著减少。结论：肾癌治疗过程中如出现视力损害，应考虑眼内转移的可能性。在治疗方面，应考虑局部治疗，如放疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊